Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT Jr, Mitchell DA, Fecci PE, Sampson JH, Dranoff G.

Expert Rev Vaccines. 2013 Jun;12(6):597-615. doi: 10.1586/erv.13.41. Review.

2.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012. Epub 2016 Jul 27. Review.

3.

Immunotherapy advances for glioblastoma.

Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT Jr, Sampson JH, Dranoff G.

Neuro Oncol. 2014 Nov;16(11):1441-58. doi: 10.1093/neuonc/nou212. Epub 2014 Sep 4. Review.

4.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

PMID:
27989218
5.

Glioblastoma antigen discovery--foundations for immunotherapy.

Azad TD, Razavi SM, Jin B, Lee K, Li G.

J Neurooncol. 2015 Jul;123(3):347-58. doi: 10.1007/s11060-015-1836-8. Epub 2015 Jun 5. Review.

PMID:
26045361
6.

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, Dhermain F.

Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Review. French.

PMID:
27032303
7.

CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.

Chonan M, Saito R, Shoji T, Shibahara I, Kanamori M, Sonoda Y, Watanabe M, Kikuchi T, Ishii N, Tominaga T.

Neuro Oncol. 2015 Nov;17(11):1453-62. doi: 10.1093/neuonc/nov090. Epub 2015 May 24.

8.

Immunomodulation for glioblastoma.

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH.

Curr Opin Neurol. 2017 Jun;30(3):361-369. doi: 10.1097/WCO.0000000000000451.

PMID:
28368867
9.

The progress of immunotherapy for glioblastoma.

Zhou Q, Wang Y, Ma W.

Hum Vaccin Immunother. 2015;11(11):2654-8. doi: 10.1080/21645515.2015.1081727. Review.

10.

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.

Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A.

Vaccine. 2015 May 28;33(23):2690-6. doi: 10.1016/j.vaccine.2015.03.095. Epub 2015 Apr 10.

11.

Challenges in clinical design of immunotherapy trials for malignant glioma.

Rolle CE, Sengupta S, Lesniak MS.

Neurosurg Clin N Am. 2010 Jan;21(1):201-14. doi: 10.1016/j.nec.2009.08.002. Review.

12.

Current challenges in designing GBM trials for immunotherapy.

Weathers SP, Gilbert MR.

J Neurooncol. 2015 Jul;123(3):331-7. doi: 10.1007/s11060-015-1716-2. Epub 2015 Jan 11. Review.

PMID:
25577401
13.

Immunotherapy for cancer in the central nervous system: Current and future directions.

Binder DC, Davis AA, Wainwright DA.

Oncoimmunology. 2015 Sep 11;5(2):e1082027. eCollection 2016 Feb. Review.

14.

Glioblastoma stem cells and stem cell-targeting immunotherapies.

Esparza R, Azad TD, Feroze AH, Mitra SS, Cheshier SH.

J Neurooncol. 2015 Jul;123(3):449-57. doi: 10.1007/s11060-015-1729-x. Epub 2015 Feb 15. Review.

PMID:
25682090
15.

Immunotherapy for the treatment of glioblastoma.

Thomas AA, Ernstoff MS, Fadul CE.

Cancer J. 2012 Jan-Feb;18(1):59-68. doi: 10.1097/PPO.0b013e3182431a73. Review.

16.

Novel vaccines for glioblastoma: clinical update and perspective.

Winograd EK, Ciesielski MJ, Fenstermaker RA.

Immunotherapy. 2016 Nov;8(11):1293-1308. Review.

17.

Immunological challenges for peptide-based immunotherapy in glioblastoma.

Mohme M, Neidert MC, Regli L, Weller M, Martin R.

Cancer Treat Rev. 2014 Mar;40(2):248-58. doi: 10.1016/j.ctrv.2013.08.008. Epub 2013 Sep 8. Review.

18.

Immunotherapy for glioblastoma: concepts and challenges.

Weiss T, Weller M, Roth P.

Curr Opin Neurol. 2015 Dec;28(6):639-46. doi: 10.1097/WCO.0000000000000249. Review.

19.

Cell-based immunotherapy against gliomas: from bench to bedside.

Bovenberg MS, Degeling MH, Tannous BA.

Mol Ther. 2013 Jul;21(7):1297-305. doi: 10.1038/mt.2013.80. Epub 2013 May 7. Review.

20.

Overview of current immunotherapeutic strategies for glioma.

Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG.

Immunotherapy. 2015;7(10):1073-104. doi: 10.2217/imt.15.75. Review.

Supplemental Content

Support Center